ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison Between Effect of Acetazolamide and NaHco3 in Prevention of Contrast Nephropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00634491
Recruitment Status : Completed
First Posted : March 13, 2008
Last Update Posted : March 13, 2008
Sponsor:
Collaborator:
Fars Heart Foundation
Information provided by:
Shiraz University of Medical Sciences

Brief Summary:
The purpose of this study is whether Acetazolamide is effective in prevention of contrast nephropathy

Condition or disease Intervention/treatment Phase
Contrast Induced Nephropathy Drug: sodium bicarbonate Drug: Acetazolamide Drug: normal salin Phase 2

Detailed Description:
Contrast induced nephropathy is one of common causes of acute renal failure many preventive protocol existed . 240 patient that underwent coronary angiography randomly divided in three groups.Group 1,2,3 will receive Bicarbonate ,Acetazolamide+Normal salin and Normal salin respectively.We compare prevalence of contrast nephropathy in each group.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Effect of Acetazolamide in Prevention of Contrast Nephropathy
Study Start Date : September 2007
Actual Primary Completion Date : February 2008
Actual Study Completion Date : February 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: 1
150 meq/l NaHco3 3cc/kg/hr one Hour before and 1cc/kg/hr 6 hour after angiography
Drug: sodium bicarbonate
150 meq/l Sodium bicarbonate 3cc/kg/hr before and 1cc/kg/hr after angiography
Other Name: no other name
Active Comparator: 2
Acetazolamide 250 mg + 1cc/kg/hr normal salin 6 hour before and after angiography
Drug: Acetazolamide
Acetazolamide 250 mg+ 1 cc/kg/hr normal salin before and after angiography
Other Name: Diamox
Active Comparator: 3
normal salin 1cc/kg/hr before and after angiography
Drug: normal salin
1 cc/kg/hr 6 hour before and after angiography
Other Name: no other name



Primary Outcome Measures :
  1. Increased base line creatinine at least 25% [ Time Frame: 24 hr later ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • patient that underwent coronary angiography

Exclusion Criteria:

  • serum Cr. more than 3 mg/dl
  • electrolyte and acid-base imbalance
  • pulmonary edema
  • allergy to Acetazolamide

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00634491


Locations
Iran, Islamic Republic of
Fars Heart Foundation , Kowsar hospital
Shiraz, Iran, Islamic Republic of
Sponsors and Collaborators
Shiraz University of Medical Sciences
Fars Heart Foundation
Investigators
Study Chair: Maryam Pakfetrat, MD Shiraz nephro-urology research center

Additional Information:
Publications of Results:
Responsible Party: Office of Vice Chancellor for research in Shiraz UMS, Shiraz University of Medical Science
ClinicalTrials.gov Identifier: NCT00634491     History of Changes
Other Study ID Numbers: 2438
First Posted: March 13, 2008    Key Record Dates
Last Update Posted: March 13, 2008
Last Verified: March 2008

Additional relevant MeSH terms:
Kidney Diseases
Urologic Diseases
Acetazolamide
Anticonvulsants
Carbonic Anhydrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Diuretics
Natriuretic Agents
Physiological Effects of Drugs